Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shanghai Henlius Biotech's Enterprise Value is HK$39,979 Mil.
Shanghai Henlius Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$115 Mil. Therefore, Shanghai Henlius Biotech's EV-to-FCF for today is 347.03.
The historical rank and industry rank for Shanghai Henlius Biotech's EV-to-FCF or its related term are showing as below:
HKSE:02696'
s EV-to-FCF Range Over the Past 10 Years
Min: -29.04 Med: -8.22 Max: 420.85
Current: 347.03
During the past 9 years, the highest EV-to-FCF of Shanghai Henlius Biotech was 420.85. The lowest was -29.04. And the median was -8.22.
HKSE:02696's EV-to-FCF is ranked worse than 95.72% of 327
companies
in the Biotechnology industry
Industry Median: 18.51
vs HKSE:02696: 347.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Henlius Biotech's PE Ratio (TTM) for today is calculated as:
Shanghai Henlius Biotech's share price for today is HK$67.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Henlius Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Henlius Biotech EV-to-FCF Related Terms
Shanghai Henlius Biotech EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02696 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's EV-to-FCF falls into.
Shanghai Henlius Biotech's current Enterprise Value is HK$39,979 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shanghai Henlius Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (HKSE:02696) has a EV-to-FCF of 347.03 as of Aug. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Henlius Biotech and its competitors. According to the industry distribution chart, Shanghai Henlius Biotech ranks #313 out of 327 companies in the Biotechnology industry, placing it in the top 95.7%.
Is Shanghai Henlius Biotech's EV-to-FCF too high?
Shanghai Henlius Biotech's current EV-to-FCF is 347.03. The Biotechnology industry median EV-to-FCF is 18.51. Shanghai Henlius Biotech's value of 347.03 is 1774.8% above this industry median. Based on the distribution chart, Shanghai Henlius Biotech ranks #313 out of 327 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #313 out of 327 companies for EV-to-FCF. This places Shanghai Henlius Biotech in the lower half of its industry. The industry median EV-to-FCF is 18.51. Shanghai Henlius Biotech's value of 347.03 is 1774.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 18.51, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Henlius Biotech's current EV-to-FCF of 347.03 is 1774.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Henlius Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 18.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Henlius Biotech's current EV-to-FCF is 347.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current EV-to-FCF is 347.03 and 1774.8% above the Biotechnology industry median of 18.51. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current EV-to-FCF is 347.03 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:02696:
EV-to-FCF: 347.03
GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
Industry Position: 1774.8% above the Biotechnology median (#313 of 327)
No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score
Get the complete analysis for HKSE:02696
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02696 has been successfully added to your 
